180 related articles for article (PubMed ID: 27739125)
1. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
2. [Vemurafenib-induced toxic epidermal necrolysis].
Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced toxic epidermal necrolysis: Is it an emerging side-effect of the drug?
Kılıç S; Özkaya E; Baykal C; Vatansever S
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e354-e355. PubMed ID: 28150343
[No Abstract] [Full Text] [Related]
4. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
Nayar N; Briscoe K; Fernandez Penas P
J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
[TBL] [Abstract][Full Text] [Related]
5. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
Jeudy G; Dalac-Rat S; Bonniaud B; Hervieu A; Petrella T; Collet E; Vabres P
Br J Dermatol; 2015; 172(5):1454-5. PubMed ID: 25384395
[No Abstract] [Full Text] [Related]
6. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
7. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.
Kato J; Hida T; Kamiya T; Sato S; Takahashi H; Torigoe T; Uhara H
JAMA Dermatol; 2018 May; 154(5):621-622. PubMed ID: 29590278
[No Abstract] [Full Text] [Related]
8. Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.
Batinac T; Hlača N; Simetić L; Valković F; Peternel S; Prpić-Massari L
Acta Derm Venereol; 2022 Feb; 102():adv00650. PubMed ID: 35146529
[No Abstract] [Full Text] [Related]
9. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R; Lecamwasam K; Purshouse K; Reed J; Middleton MR; Fearfield L
Br J Dermatol; 2014 Apr; 170(4):997-9. PubMed ID: 24359127
[No Abstract] [Full Text] [Related]
10. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib.
Nühnen VP; Schön MP; Mössner R
J Dtsch Dermatol Ges; 2018 Feb; 16(2):199-201. PubMed ID: 29328518
[No Abstract] [Full Text] [Related]
11. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
12. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab therapy before vemurafenib administration induces a severe skin rash.
Imafuku K; Yoshino K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):e169-e171. PubMed ID: 27546003
[No Abstract] [Full Text] [Related]
14. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
15. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
[No Abstract] [Full Text] [Related]
16. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment.
Komori T; Otsuka A; Kaku Y; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e474-e475. PubMed ID: 28426905
[No Abstract] [Full Text] [Related]
17. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
18. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.
Poduje S; Brozić JM; Prkačin I; Delaš Aždajić M; Goren A
Dermatol Ther; 2020 Jan; 33(1):e13174. PubMed ID: 31750971
[TBL] [Abstract][Full Text] [Related]
20. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
Eser Öztürk H; Süllü Y
Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]